HALLE (SAALE), Germany, 22 May 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), announces that the company is scheduled to attend the following conferences: (1) 2019 BIO […]
HALLE (SAALE), Germany, 16 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD), announced today its first quarter business update for the period ending March 31, 2019. The […]
HALLE (SAALE), Germany, 9 May 2019 – Probiodrug AG (Euronext Amsterdam: PBD, ISIN: DE0007921835), is focusing on the discovery and development of drugs acting on enzymes which […]
HALLE (SAALE), Germany, 18 April 2019 – Probiodrug AG (Euronext Amsterdam: PBD; ISIN: DE0007921835), invites all shareholders to Probiodrugs ordinary general meeting of shareholders to be […]
Consortium of strategic investors led by Dr. Claus Christiansen founder and chairman of the board of Nordic Bioscience, Denmark, invests EUR 6.2 million Proceeds used to […]
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA Probiodrug raises EUR 8.2 million from investors in successful private […]
The shares are trading on XETRA, the electronic trading platform of Deutsche Börse. HALLE (SAALE), Germany, 04 APRIL 2019 – Shares in Probiodrug AG, (Euronext […]
Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) NIH grant of 15million USD received PQ912 Phase 2b core program prepared HALLE (SAALE), […]
HALLE (SAALE), Germany, 21 March 2019 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]